

Non-Small Cell Lung Cancer Treatments

Reference Number: RDF1696-23

Date of Response: 08/08/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon University Healthcare NHS Foundation Trust, can you please answer the following question regarding cancer treatments across the UK:

- In the past 3 months, how many early-stage (non-metastatic or Stages 1-3) Non-small cell lung cancer patients received the following treatments:*

Atezolizumab

Durvalumab

Nivolumab

Pembrolizumab

Chemotherapy (Platinum, Taxane, Vinorelbine, Gemcitabine, Pemetrexed) only

Radiotherapy only

Chemotherapy + radiotherapy

Answer: Please see table below. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤ 5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

Regimen	Total
<i>Atezolizumab</i>	≤ 5
<i>Durvalumab</i>	8
<i>Nivolumab</i>	Nil
<i>Pembrolizumab</i>	11
<i>Chemotherapy (Platinum, Taxane, Vinorelbine, Gemcitabine, Pemetrexed) only</i>	7
<i>Radiotherapy only</i>	13
<i>Chemotherapy + radiotherapy</i>	≤ 5